Skip to content
Screener

Stoke Therapeutics, Inc. STOK Q2 2026 earnings

Reported August 3, 2026 · After market close

Revenue$9.3MBeat by $4.4M
EPS-$0.93Miss by $0.14
Revenue estimate$4.9M
EPS estimate-$0.80
“We have made significant progress across our business this year, including the rapid enrollment of 162 patients into the Phase 3 EMPEROR study and progression of these patients through key study milestones with the first patients now approaching the end of the 52-week treatment period. With no treatment discontinuations to date in EMPEROR, and supportive four-year safety and efficacy data from the ongoing open-label extension studies, we have confidence in the potential of zorevunersen to change the course of Dravet syndrome. We look forward to our upcoming pre-NDA meeting with the FDA to align on the overall data package content and timing, as well as the statistical analysis plan, as we prepare to initiate our rolling U.S. NDA submission in the first quarter of 2027.”
Ian F. Smith

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.2M
EPS estimate-$0.88

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$2.14B+102%
Enterprise value$1.98B+106%
P/S66.6×+61.3×

FAQ

When did Stoke Therapeutics, Inc. report Q2 2026 earnings?
Stoke Therapeutics, Inc. (STOK) reported Q2 2026 earnings on August 3, 2026 after market close.
What were Stoke Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Stoke Therapeutics, Inc. reported revenue of $9.3M and eps of $-0.93 for Q2 2026.
Did Stoke Therapeutics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $4.9M by $4.4M. EPS missed the consensus estimate of $-0.80 by $0.14.
How did Stoke Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 32.5% from $13.8M a year earlier and eps declined 132.5% from $-0.40.
Where can I find Stoke Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-330537) and the 10-Q periodic report (0001193125-26-330557) directly on SEC EDGAR. The filing index links above go to sec.gov.